[HTML][HTML] Hepatitis B flares in chronic hepatitis B: pathogenesis, natural course, and management
ML Chang, YF Liaw - Journal of hepatology, 2014 - Elsevier
Hepatitis B flare, defined as an event with abrupt rise of alanine aminotransferase (ALT)
levels to> 5 times the upper limit of normal during chronic hepatitis B virus (HBV) infection, is …
levels to> 5 times the upper limit of normal during chronic hepatitis B virus (HBV) infection, is …
[HTML][HTML] Management of chronic hepatitis B infection: current treatment guidelines, challenges, and new developments
Chronic hepatitis B (CHB) virus infection is a global public health problem, affecting more
than 400 million people worldwide. The clinical spectrum is wide, ranging from a subclinical …
than 400 million people worldwide. The clinical spectrum is wide, ranging from a subclinical …
Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial)
Q Ning, M Han, Y Sun, J Jiang, D Tan, J Hou… - Journal of …, 2014 - Elsevier
Background & Aims Durable post-treatment response is uncommon in chronic hepatitis B
(CHB) patients on nucleos (t) ide analogue therapy. Response, response predictors and …
(CHB) patients on nucleos (t) ide analogue therapy. Response, response predictors and …
[PDF][PDF] No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B
KM Kitrinos, A Corsa, Y Liu, J Flaherty… - …, 2014 - Wiley Online Library
One major challenge in the treatment of chronic hepatitis B is to maintain long‐term viral
suppression without promoting the selection of drug‐resistant mutations. We analyzed data …
suppression without promoting the selection of drug‐resistant mutations. We analyzed data …
Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA
HLY Chan, CK Chan, AJ Hui, S Chan, F Poordad… - Gastroenterology, 2014 - Elsevier
Background & Aims Little is known about the benefit of antiviral therapy for hepatitis B e
antigen (HBeAg)− positive patients with high viral load and normal levels of alanine …
antigen (HBeAg)− positive patients with high viral load and normal levels of alanine …
Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B
S Fung, P Kwan, M Fabri, A Horban, M Pelemis… - Gastroenterology, 2014 - Elsevier
Background & Aims Tenofovir disoproxil fumarate (TDF) is active against lamivudine-
resistant hepatitis B virus (HBV) infection, but data to support its clinical efficacy in this …
resistant hepatitis B virus (HBV) infection, but data to support its clinical efficacy in this …
Mortality, liver transplantation, and hepatocellular carcinoma among patients with chronic hepatitis B treated with entecavir vs lamivudine
YS Lim, S Han, NY Heo, JH Shim, HC Lee, DJ Suh - Gastroenterology, 2014 - Elsevier
Background & Aims Little is known about whether the antiviral agent entecavir is more
effective than a less potent drug, lamivudine, in reducing the risk of death and hepatocellular …
effective than a less potent drug, lamivudine, in reducing the risk of death and hepatocellular …
HB sAg quantification: useful for monitoring natural history and treatment outcome
M Martinot‐Peignoux, M Lapalus, T Asselah… - Liver …, 2014 - Wiley Online Library
The template of hepatitis B virus transcription, the covalently closed circular DNA (ccc DNA),
plays a key role in the life cycle of the virus and permits the persistence of infection. It has …
plays a key role in the life cycle of the virus and permits the persistence of infection. It has …
Kinetics of hepatitis B surface antigen loss in patients with HBeAg-positive chronic hepatitis B treated with tenofovir disoproxil fumarate
P Marcellin, M Buti, Z Krastev, RA de Man… - Journal of …, 2014 - Elsevier
Background & Aims In a study of 266 chronic hepatitis B e antigen (HBeAg)-positive
patients, 23 experienced hepatitis B surface antigen (HBsAg) loss with up to 5 years of …
patients, 23 experienced hepatitis B surface antigen (HBsAg) loss with up to 5 years of …
A randomized, open-label clinical study of combined pegylated Interferon Alfa-2a (40KD) and Entecavir treatment for Hepatitis B “e” Antigen–Positive Chronic …
Q Xie, H Zhou, X Bai, S Wu, JJ Chen… - Clinical infectious …, 2014 - academic.oup.com
Randomized, Open-Label Clinical Study of Combined Pegylated Interferon Alfa-2a (40KD)
and Entecavir Treatment for Hepatitis B “e” Antigen–Positive Chronic Hepatitis B | Clinical …
and Entecavir Treatment for Hepatitis B “e” Antigen–Positive Chronic Hepatitis B | Clinical …